These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37985384)

  • 1. Characterization of Expression and Function of the Formins FHOD1, INF2, and DAAM1 in HER2-Positive Breast Cancer.
    Peippo M; Gardberg M; Kronqvist P; Carpén O; Heuser VD
    J Breast Cancer; 2023 Dec; 26(6):525-543. PubMed ID: 37985384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple formin proteins participate in glioblastoma migration.
    Heuser VD; Kiviniemi A; Lehtinen L; Munthe S; Kristensen BW; Posti JP; Sipilä JOT; Vuorinen V; Carpén O; Gardberg M
    BMC Cancer; 2020 Jul; 20(1):710. PubMed ID: 32727404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formin Proteins FHOD1 and INF2 in Triple-Negative Breast Cancer: Association With Basal Markers and Functional Activities.
    Heuser VD; Mansuri N; Mogg J; Kurki S; Repo H; Kronqvist P; Carpén O; Gardberg M
    Breast Cancer (Auckl); 2018; 12():1178223418792247. PubMed ID: 30158824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FHOD1, a formin upregulated in epithelial-mesenchymal transition, participates in cancer cell migration and invasion.
    Gardberg M; Kaipio K; Lehtinen L; Mikkonen P; Heuser VD; Talvinen K; Iljin K; Kampf C; Uhlen M; Grénman R; Koivisto M; Carpén O
    PLoS One; 2013; 8(9):e74923. PubMed ID: 24086398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The formins FHOD1 and INF2 regulate inter- and intra-structural contractility of podosomes.
    Panzer L; Trübe L; Klose M; Joosten B; Slotman J; Cambi A; Linder S
    J Cell Sci; 2016 Jan; 129(2):298-313. PubMed ID: 26621033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
    Hosonaga M; Arima Y; Sugihara E; Kohno N; Saya H
    Cancer Sci; 2014 Jul; 105(7):779-87. PubMed ID: 24754246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
    Baldassarre T; Truesdell P; Craig AW
    Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
    O'Shea J; Cremona M; Morgan C; Milewska M; Holmes F; Espina V; Liotta L; O'Shaughnessy J; Toomey S; Madden SF; Carr A; Elster N; Hennessy BT; Eustace AJ
    Oncotarget; 2017 Oct; 8(49):85120-85135. PubMed ID: 29156708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FHOD1 and FMNL1 formin proteins in intestinal gastric cancer: correlation with tumor-infiltrating T lymphocytes and molecular subtypes.
    Mansuri N; Heuser VD; Birkman EM; Lintunen M; Ålgars A; Sundström J; Ristamäki R; Carpén O; Lehtinen L
    Gastric Cancer; 2021 Nov; 24(6):1254-1263. PubMed ID: 34115237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
    Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
    Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the Rac-binding partner FHOD1 induces actin stress fibers via a ROCK-dependent mechanism.
    Gasteier JE; Madrid R; Krautkrämer E; Schröder S; Muranyi W; Benichou S; Fackler OT
    J Biol Chem; 2003 Oct; 278(40):38902-12. PubMed ID: 12857739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.
    Singel SM; Batten K; Cornelius C; Jia G; Fasciani G; Barron SL; Wright WE; Shay JW
    Breast Cancer Res; 2014 Mar; 16(2):R28. PubMed ID: 24642040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways.
    Ren W; Liu Y; Wan S; Fei C; Wang W; Chen Y; Zhang Z; Wang T; Wang J; Zhou L; Weng Y; He T; Zhang Y
    PLoS One; 2014; 9(5):e96816. PubMed ID: 24805814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.
    Lam PB; Burga LN; Wu BP; Hofstatter EW; Lu KP; Wulf GM
    Mol Cancer; 2008 Dec; 7():91. PubMed ID: 19077306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
    BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
    Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.